以嶺藥業(002603.SZ):與順騰國際籤諒解備忘錄 着力國際品牌及銷售合作
格隆匯10月13日丨以嶺藥業(002603.SZ)宣佈,2020年10月12日,公司與順騰國際(00932.HK)簽訂了《諒解備忘錄》,就雙方項目合作事宜達成初步合作意向。主要體現在國際品牌及銷售合作,包含國際電商平台及管理,包括:
1、產品在港澳銷售及品牌合作:以御藥堂目前在香港及澳門兩大的策略合作分銷代理店鋪夥伴總共620家實體門店、與100個駐店促銷員專櫃為基礎(已經佔有港澳一半的通路門店),對以嶺產品進行註冊和銷售。同時以御藥堂目前在中國香港和澳門地區、東南亞及其他國家的電商平台為基礎,對以嶺的產品進行在線銷售。
2、產品在中國內地的銷售及品牌合作:以嶺引進順騰產品到中國內地進行經銷。在產品沒有取得中國大陸藥監部門產品註冊批文的階段,通過與以嶺共同合作的跨境電商平台進行合規銷售,並進行跨境電商銷售的大數據管理與業務。同時啟動順騰產品在中國大陸藥監部門的註冊申請,取得註冊批文後,雙方利用以嶺目前在中國大陸直接觸達的10萬家藥房、以及通過渠道能夠覆蓋的30萬家藥房,合共40萬家進行線下合規銷售。
3、醫療合作:利用御藥堂在分銷代理店鋪網絡內的多年中醫門診實體店服務為基礎,通過遠程在線診斷、或派遣以嶺醫生團隊到香港及澳門拓展中醫門診服務,同時建立品牌國際化。此外與銷售以嶺和御藥堂旗下多項核心旗艦中醫藥及保健產品,並建立自有的臨牀數據庫,提供與以嶺作為未來大灣區基礎數據。
順騰國際(00932.HK)與其附屬公司主要在香港從事配方、推廣、銷售及分銷中醫藥及保健以及美容補品及產品業務,並在大中華區提供在線電子商務推廣業務。目前御藥堂旗下擁有八個專有品牌、一個分銷代理的自有品牌,合共生產159款中成藥、保健產品,美容及纖體產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.